# Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

> **NCT06094101** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 30 (estimated)

## Conditions studied

- Ewing Sarcoma
- Rhabdomyosarcoma
- Synovial Sarcoma

## Interventions

- **BIOLOGICAL:** Peptide vaccine IPX

## Key facts

- **NCT ID:** NCT06094101
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-19
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094101, "Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06094101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*